What our research found
Trimi Health presents itself as the technology and service platform rather than the medical practice or pharmacy. Its current marketing site names Arora Health as the 50-state clinical network, Sean Arora, MD as medical director, and VialsRx or GreenwichRx as the pharmacies that may dispense patient-specific compounded prescriptions.
The live intake creates a material identity conflict. Its linked terms still say clinicians are employed or contracted by Beluga Health, P.A. or similar professional entities. The current site terms say only licensed healthcare providers, without naming Arora or Beluga. A patient should confirm the legal medical group, clinician, and pharmacy in the consent, prescription, and label.
The current site describes a five-to-ten-minute health questionnaire, provider review within 24 hours, and no required video visit. The clinician reviews history, medications, and eligibility and may prescribe only when medically appropriate. One treatment FAQ says a BMI of 22 generally permits beginning intake, while the medical review policy cites prescribing thresholds of BMI 30 or BMI 27 with a weight-related condition. The lower figure is an intake threshold, not a promise of clinical eligibility.
Trimi offers two canonical compounded injection ingredients: semaglutide and tirzepatide. The program says a clinician may adjust dose without changing the plan price. Exact concentration, additives, injection volume, quantity, storage, beyond-use date, and dispensing pharmacy remain prescription-specific.
FDA states that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. FDA also states that section 503A pharmacies are primarily overseen day to day by state boards and are not subject to current good manufacturing practice requirements. Trimi's medical review policy incorrectly says its 503A partners operate under cGMP, so the draft does not repeat that claim.
FDA's current GLP-1 compounding notice says semaglutide and tirzepatide are not on the drug shortage list. Section 503A restricts regular or inordinate compounding of essentially copies unless a prescriber documents a patient-specific change that produces a significant difference. Trimi does not publish that patient-specific rationale before intake, so eligibility for a compounded preparation must be established by the prescriber rather than assumed from the marketing page.
Compounded semaglutide costs $175 month to month, $435 for three months, $720 for six months, or $1,188 for twelve months. The effective monthly rates are $175, $145, $120, and $99. Their unweighted mean is $134.75, displayed as Avg. $135/mo.
Compounded tirzepatide costs $235 month to month, $597 for three months, $1,050 for six months, or $1,500 for twelve months. The effective monthly rates are $235, $199, $175, and $125. Their unweighted mean is $183.50, displayed as Avg. $184/mo.
Quarterly, six-month, and annual tiers are commitments for their stated terms. The annual monthly equivalents are not month-to-month prices. Current pages say longer plans may be paid upfront or through buy-now-pay-later financing, and six- and twelve-month programs ship three vials every three months rather than the entire commitment at once.
Trimi advertises $50 off the first billing cycle under code 50OFF. One current page says the code is applied automatically, while another presents it as a code. The promotion is temporary and excluded from both card averages. It is also absent beneath the CTA because the Katalys application is pending and no compatible tracking link or customer benefit has been issued.
Current first-charge language conflicts. A pricing article says the first charge occurs after clinician approval. The refund policy describes a patient who has already paid but may cancel for a full refund before the clinician issues the prescription. Confirm when the card is charged, the amount, the commitment, financing terms, and renewal mechanics before submitting payment.
The prescription is the cancellation cutoff for the current order. Before issuance, the order can be canceled for a full refund. Once the clinician issues the prescription, that order is final and non-refundable even if the pharmacy has not compounded or shipped it. Ending a plan stops future charges only after Trimi confirms the request.
Multi-month plans are not prorated. The current policy says early exits from discounted terms are reviewed case by case. It also advertises a six-month money-back promise for unresolved dissatisfaction or no net weight loss, but eligibility depends on continuous treatment, adherence, provider check-ins, portal weight logs, and a claim within 30 days of the six-month mark.
Medical disqualification triggers an automatic full refund. Damaged or missing packages must be reported within 24 hours. A verified damaged shipment may be replaced or refunded, while a carrier-confirmed delivery shifts the missing-package claim to the carrier. Approved refund decisions are stated to take two to four business days, followed by bank processing.
Shipping pages agree on free temperature-controlled packaging, tracking, and overnight transit once compounding is complete. They do not agree on total time. The homepage says most orders arrive in two to four days, a shipping article outlines approximately five to seven days, and the how-it-works page says first dose in about a week. Treat these as estimates rather than a guarantee.
Current first-party guidance says routine laboratory work is not typically required but may be recommended for thyroid, kidney, or blood-sugar monitoring. The clinician may require testing based on medical history, current medication, symptoms, or state practice rules. No standard included lab panel appears in the public plan list.
Trimi says it does not bill insurance and no prior authorization is needed for the cash-pay program. It advertises HSA and FSA eligibility. Reimbursement still depends on the benefit administrator and documentation, so retain the prescription and itemized receipt and verify eligibility before relying on tax-advantaged funds.
The current site advertises service in all 50 states and Washington, D.C. Actual access remains subject to the patient's location, clinician licensure, clinical eligibility, pharmacy licensure and capacity, and the legality of the patient-specific compounded prescription.
Support includes 855-200-2563 Monday through Friday from 9 a.m. to 6 p.m. Eastern, care@trytrimi.com with a stated reply within 24 hours, and a patient portal open around the clock. These channels are not emergency care.
One Katalys application is pending for Trimi under offer 1614. The recorded payout is $200 and the discovery EPC is $14.60. No tracking URL has been issued. Payout and EPC affected work order only and did not change the score, findings, prices, or CTA.
- Two canonical ingredient cards average $135 per month for semaglutide and $184 per month for tirzepatide across four standard terms.
- The current site names Arora Health, VialsRx, and GreenwichRx, while the live intake still links to older Beluga Health terms.
- The annual floor prices require twelve-month commitments, and the current order becomes final once a prescription is issued.
- Free cold-chain shipping, portal messaging, supplies, and dose adjustments are included, but official total-delivery estimates range from two to seven days.
